GlassScriptPhysician profile
Ralph Kenneth Ablaseau
NPI 1982869715
$8,780.19
in general payments reported to CMS, 2019-2025
26 companies · $2,111 in 2025
The $2,111 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $345 · 2022: $625 · 2023: $1,175 · 2024: $4,524 · 2025: $2,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,940 · Consulting Fee: $2,040 · Travel and Lodging: $831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,939.78 |
| Consulting Fee | $2,040.00 |
| Travel and Lodging | $830.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Global Services, LLC | $3,079.06 | 2024 | Spravato |
| Abbvie INC. | $1,343.76 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $660.61 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $580.99 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $561.22 | 2023-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $521.80 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $290.03 | 2023-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $265.73 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $180.87 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $173.30 | 2022-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $140.71 | 2022-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $134.50 | 2023-2024 | Jornay Pm |
| Corium, LLC | $123.82 | 2022-2025 | Azstarys |
| Janssen Scientific Affairs, LLC | $115.00 | 2025 | Spravato |
| Lundbeck LLC | $99.33 | 2021-2024 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $94.97 | 2021-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $89.80 | 2023-2024 | Quviviq |
| Biogen, INC. | $75.18 | 2024-2025 | Zurzuvae |
| Axsome Therapeutics, INC. | $70.16 | 2024-2025 | Auvelity |
| Noven Therapeutics, LLC | $59.80 | 2024 | Secuado, Xelstrym |
| Sunovion Pharmaceuticals INC. | $37.20 | 2021-2022 | |
| Harmony Biosciences LLC | $19.32 | 2025 | |
| Tris Pharma INC | $17.80 | 2024 | Dyanavel Xr |
| Bausch Health US, LLC | $17.41 | 2021 | |
| Almatica Pharma LLC | $14.63 | 2022 | |
| Merck Sharp & Dohme LLC | $13.19 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Ablaseau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.